Aurinia Pharmaceuticals I... (AUPH)
8.18
0.08 (0.99%)
At close: Apr 25, 2025, 2:47 PM
Aurinia Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License, Royalty and Collaboration Revenue Revenue | 12.27M | 2.16M | 2.23M | 42.31M | 13.73M | 394K | 72K | 28.33M | 25.5M | 28.15M | 21.49M | 23.38M | 14.64M | 6.59M | 30K |
| License, Royalty and Collaboration Revenue Revenue Growth | +466.91% | -2.96% | -94.73% | +208.10% | +3385.79% | +447.22% | -99.75% | +11.07% | -9.40% | +30.97% | -8.06% | +59.69% | +122.09% | +21870.00% | n/a |
| Product Revenue | 55.5M | 55.03M | 48.07M | n/a | 40.78M | 41.1M | 34.34M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +0.86% | +14.47% | n/a | n/a | -0.78% | +19.70% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|
| Japan Revenue | 17.55M | 31.48M | n/a | 50M | 200K | 345K | 300K |
| Japan Revenue Growth | -44.24% | n/a | -100.00% | +24900.00% | -42.03% | +15.00% | n/a |
| Other Country Revenue | n/a | 89K | 117K | n/a | n/a | n/a | n/a |
| Other Country Revenue Growth | -100.00% | -23.93% | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 157.96M | 102.46M | 45.49M | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +54.17% | +125.25% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 39.64M | 44.93M | 47.7M | 50.07M | 47.76M | 47.08M | 50.12M | 47.47M | 52.17M | 51.53M | 45.2M | 44.24M | 44.13M | 43.79M | 39.28M | 38.78M | 31.07M | 15.54M | 11.06M | 7.25M | 6.06M | 4.95M | 3.9M | 3.5M | 2.92M | 3.46M | 3.79M | 3.12M | 2.65M | 2.9M | 3.43M | 2.23M | 1.72M | 1.83M | 1.19M | 1.56M | 1.38M | 1.41M | 1.91M |
| Selling, General, and Administrative Revenue Growth | -11.78% | -5.79% | -4.75% | +4.84% | +1.44% | -6.07% | +5.58% | -9.00% | +1.24% | +14.02% | +2.16% | +0.26% | +0.78% | +11.47% | +1.30% | +24.82% | +99.91% | +40.50% | +52.65% | +19.55% | +22.54% | +26.79% | +11.52% | +19.67% | -15.57% | -8.68% | +21.58% | +17.66% | -8.65% | -15.35% | +53.88% | +29.78% | -6.49% | +53.94% | -23.79% | +13.33% | -2.40% | -25.77% | n/a |
| Research and Development Revenue | 3.05M | 4.08M | 5.55M | 10.23M | 13.61M | 12.65M | 13.16M | 9.87M | 10.97M | 11.53M | 12.62M | 11.15M | 20.07M | 10.09M | 9.83M | 13.17M | 4.8M | 11.08M | 13.84M | 13.29M | 17.79M | 11.15M | 10.63M | 10.84M | 11.15M | 10.5M | 8.89M | 8.69M | 10.81M | 7.11M | 7.33M | 5.46M | 3.34M | 2.41M | 3.32M | 3.65M | 4.67M | 4.33M | 3.33M |
| Research and Development Revenue Growth | -25.32% | -26.50% | -45.73% | -24.82% | +7.55% | -3.86% | +33.31% | -10.05% | -4.79% | -8.68% | +13.19% | -44.44% | +98.85% | +2.62% | -25.35% | +174.44% | -56.66% | -19.94% | +4.09% | -25.29% | +59.53% | +4.90% | -1.92% | -2.81% | +6.17% | +18.20% | +2.26% | -19.58% | +52.06% | -2.98% | +34.11% | +63.44% | +38.90% | -27.62% | -8.98% | -21.80% | +7.85% | +30.03% | n/a |